In vitro screening of tumoricidal properties of international medicinal herbs: Part II

Phytotherapy Research

Volumn 24, Issue 12, 2010, Pages 1813-1824

  Mazzio, Elizabeth A ^a   Soliman, Karam F A ^a  

^a FLORIDA A AND M UNIVERSITY   (United States)

Author keywords

beth root; bible; cancer; galbanum; herbs; Lithospermum erythrorhizon root; screening

Indexed keywords

ANGELICA SINENSIS EXTRACT; ASAFETIDA EXTRACT; ATRACTYLODES MACROCEPHALA EXTRACT; BETH ROOT EXTRACT; CANNABIS; CHINESE DRUG; FANG JI; GALBANUM EXTRACT; GROMWELL ROOT EXTRACT; HAI FENG TENG; HONG TIAO ZI CAO; HOU PO; HUANG LIAN; NATURAL PRODUCT; TIAN SAN QI; TURMERIC; TURMERIC EXTRACT; UNCLASSIFIED DRUG; WU JIA PI; YUAN ZHI; ZE XIE;

ANGIOSPERM; ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; APIALES; ARTICLE; BORAGINACEAE; CELL DEATH; CELL VIABILITY; CHINESE MEDICINE; CONTROLLED STUDY; DANDELION; DRUG CYTOTOXICITY; DRUG POTENCY; FENNEL; HERBAL MEDICINE; IN VITRO STUDY; JUNIPERUS; LC 50; LOQUAT; NEUROBLASTOMA; NONHUMAN; RHUBARB; TAXONOMY; TEA; TRILLIUM;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; APIACEAE; BORAGINACEAE; CELL LINE, TUMOR; DRUG SCREENING ASSAYS, ANTITUMOR; DRUGS, CHINESE HERBAL; LILIACEAE; MICE; NEUROBLASTOMA; PLANT EXTRACTS; PLANTS, MEDICINAL;

APIACEAE; ASTERIDS; BORAGINACEAE; CARYOPHYLLALES; DICOTYLEDONEAE; DILLENIIDAE; FERULA GUMMOSA; HAMAMELIDIDAE; LILIACEAE; LITHOSPERMUM ERYTHRORHIZON; MAGNOLIIDAE; MAGNOLIOPHYTA; ROSIDAE; TRILLIUM;

EID: 78649659235     PISSN: 0951418X     EISSN: 10991573     Source Type: Journal    
DOI: 10.1002/ptr.3191     Document Type: Article

References (47)

1. Advance Data from Vital and Health Statistics. CDC. May 27, 2004.
2. Alkhatib R, Hennebelle T, Joha S, et al,. 2008. Activity of elaeochytrin A from Ferula elaeochytris on leukemia cell lines. Phytochemistry 69: 2979-2983.
3. Ahn BZ, Baik KU, Kweon GR, Lim K, Hwang BD., 1995. Acylshikonin analogues: synthesis and inhibition of DNA topoisomerase-I. J Med Chem 38: 1044-1047.
4. Bajgrowicz JA, Berg-Schultz K, Brunner G., 2003. Substituted hepta-1,6-dien-3-ones with green/fruity odours green/galbanum olfactophore model. Bioorg Med Chem 11: 2931-2946.
5. Barthomeuf C, Demeule M, Grassi J, Saidkhodjaev A, Beliveau R., 2006. Conferone from Ferula schtschurowskiana enhances vinblastine cytotoxicity in MDCK-MDR1 cells by competitively inhibiting P-glycoprotein transport. Planta Med 72: 634-639.
6. Barthomeuf C, Lim S, Iranshahi M, Chollet P., 2008. Umbelliprenin from Ferula szowitsiana inhibits the growth of human M4Beu metastatic pigmented malignant melanoma cells through cell-cycle arrest in G1 and induction of caspase-dependent apoptosis. Phytomedicine 15: 103-111.
7. Bensky D, Clavey S, Stoger E, Gamble A, Bensky LL., 2004. Chinese Herbal Medicine 3rd edn. Materia Medica. Eastland Press: Seattle, WA.
8. Blot WJ., 1997. Vitamin/mineral supplementation and cancer risk: international chemoprevention trials. Proc Soc Exp Biol Med 216: 291-296.
9. Boon H, Stewart M, Kennard MA, et al,. 2000. Use of complementary/ alternative medicine by breast cancer survivors in Ontario: prevalence and perceptions. J Clin Oncol 18: 2515-2521.
10. Chakraborty S, Roy M, Taraphdar AK, Bhattacharya RK., 2004. Cytotoxic effect of root extract of Tiliacora racemosa and oil of Semecarpus anacardium nut in human tumour cells. Phytother Res 18: 595-600.
11. Cho MH, Paik YS, Hahn TR., 1999. Physical stability of shikonin derivatives from the roots of Lithospermum erythrorhizon cultivated in Korea. J Agric Food Chem 47: 4117-4120.
12. Clerici CA, Veneroni L, Giacon B, Mariani L, Fossati-Bellani F., 2009. Complementary and alternative medical therapies used by children with cancer treated at an Italian pediatric oncology unit. Pediatr Blood Cancer 53: 599-604.
13. Conney AH., 2003. Enzyme induction and dietary chemicals as approaches to cancer chemoprevention: the Seventh DeWitt S. Goodman Lecture. Cancer Res 63: 7005-7031.
14. Cui XR, Tsukada M, Suzuki N, et al,. 2008. Comparison of the cytotoxic activities of naturally occurring hydroxyanthraquinones and hydroxynaphthoquinones. Eur J Med Chem 43: 1206-1215.
15. Dy GK, Bekele L, Hanson LJ, et al,. 2004. Complementary and alternative medicine use by patients enrolled onto phase I clinical trials. J Clin Oncol 22: 4810-4815.
16. Ferrucci LM, McCorkle R, Smith T, Stein KD, Cartmel B., 2009. Factors related to the use of dietary supplements by cancer survivors. J Altern Complement Med 15: 673-680.
17. Finklestein JZ, Tittle K, Meshnik R, Weiner J., 1975. Murine neuroblastoma, further evaluation of the C1300 model with single antitumor agents. Cancer Chemother Rep 59: 975-983.
18. Gamal-Eldeen AM, Hegazy ME., 2010. A crystal lapiferin derived from Ferula vesceritensis induces apoptosis pathway in MCF-7 breast cancer cells. Nat Prod Res 24: 246-257.
19. Genc RE, Senol S, Turgay AS, Kantar M., 2009. Complementary and alternative medicine used by pediatric patients with cancer in western Turkey. Oncol Nurs Forum 36: E159-E164.
20. Gerson-Cwilich R, Serrano-Olvera A, Villalobos-Prieto A., 2006. Complementary and alternative medicine (CAM) in Mexican patients with cancer. Clin Transl Oncol 8: 200-207.
21. Ghosh A, Banerji A, Mandal S, Banerji J., 2009. A new sesquiterpenoid coumarin from Ferula assafoetida. Nat Prod Commun 4: 1023-1024.
22. Hayes PY, Lehmann R, Penman K, Kitching W, De Voss JJ., 2009. Steroidal saponins from the roots of Trillium erectum (Beth root). Phytochemistry 70: 105-113.
23. Hisa T, Kimura Y, Takada K, Suzuki F, Takigawa M., 1998. Shikonin, an ingredient of Lithospermum erythrorhizon, inhibits angiogenesis in vivo and in vitro. Anticancer Res 18: 783-790.
24. Hou Y, Guo T, Wu C, He X, Zhao M., 2006. Effect of shikonin on human breast cancer cells proliferation and apoptosis in vitro. Yakugaku Zasshi 126: 1383-1386.
25. Hu Z, Yang X, Ho PC, et al,. 2005. Herb-drug interactions, a literature review. Drugs 65: 1239-1282.
26. Ishida T, Sakaguchi I., 2007. Protection of human keratinocytes from UVB-induced inflammation using root extract of Lithospermum erythrorhizon. Biol Pharm Bull 30: 928-934.
27. Klebe RJ, Ruddle FH., 1969. Neuroblastoma, cell culture analysis of a differentiating stem cell system. J Cell Biol 43: 69A.
28. Kraft K., 2009. Complementary/alternative medicine in the context of prevention of disease and maintenance of health. Prev Med 49: 88-92.
29. Kristoffersen AE, Fønnebø V, Norheim AJ., 2009. Do cancer patients with a poor prognosis use complementary and alternative medicine more often than others? J Altern Complement Med 15: 35-40.
30. Kumar NB, Allen K, Bell H., 2005. Perioperative herbal supplement use in cancer patients, potential implications and recommendations for presurgical screening. Cancer Control 12: 149-157.
31. Lee CL, Chiang LC, Cheng LH, et al,. 2009. Influenza A (H (1) N (1)) Antiviral and cytotoxic agents from Ferula assafoetida. J Nat Prod 72: 1568-1572.
32. 2 extraction. J Cosmet Sci 59: 431-440.
33. Lee JH, Choi S, Lee Y, et al,. 2010. Herbal compound farnesiferol C exerts antiangiogenic and antitumor activity and targets multiple aspects of VEGFR1 (Flt1) or VEGFR2 (Flk1) signaling cascades. Mol Cancer Ther 9: 389-399.
34. Lin JH, 1998. Applications and limitations of interspecies scaling and in vitro extrapolation in pharmacokinetics. Drug Metab Dispos 26: 1202-1212.
35. Mazzio EA, Soliman KF., 2009. In vitro screening for the tumoricidal properties of international medicinal herbs. Phytother Res 23: 385-398.
36. Mazzio E, Yoon KJ, Soliman KF., 2003. Acetyl-L-carnitine cytoprotection against 1-methyl-4-phenylpyridinium toxicity in neuroblastoma cells. Biochem Pharmacol 66: 297-306.
37. Melnick SJ., 2006. Developmental therapeutics, review of biologically based CAM therapies for potential application in children with cancer, part I. J Pediatr Hematol Oncol 28: 221-230.
38. Molassiotis A, Browall M, Milovics L, Panteli V, Patiraki E, Fernandez-Ortega P., 2006. Complementary and alternative medicine use in patients with gynecological cancers in Europe. Int J Gynecol Cancer 16 (Suppl 1): 219-224.
39. Ohno S, Ohno Y, Suzuki N, Soma G, Inoue M., 2009. High-dose vitamin C (ascorbic acid) therapy in the treatment of patients with advanced cancer. Anticancer Res 29: 809-815.
40. Owens B, Jackson M, Berndt A., 2009. Complementary therapy used by Hispanic women during treatment for breast cancer. J Holist Nurs 27: 167-176.
41. Richardson MA, Sanders T, Palmer JL, Greisinger A, Singletary SE., 2000. Complementary/alternative medicine use in a comprehensive cancer center and the implications for oncology. J Clin Oncol 18: 2505-2514.
42. Rosenberg Zand RS, Jenkins DJ, Diamandis EP., 2002. Flavonoids and steroid hormone-dependent cancers. J Chromatogr B Analyt Technol Biomed Life Sci 777: 219-232.
43. Scott JA, Kearney N, Hummerston S, Molassiotis A., 2005. Use of complementary and alternative medicine in patients with cancer: a UK survey. Eur J Oncol Nurs 9: 131-137.
44. Tarhan O, Alacacioglu A, Somali I, et al,. 2009. Complementary- alternative medicine among cancer patients in the western region of Turkey. J Buon 14: 265-269.
45. van Tonder E, Herselman MG, Visser J., 2009. The prevalence of dietary-related complementary and alternative therapies and their perceived usefulness among cancer patients. J Hum Nutr Diet 22: 528-535.
46. Yates JS, Mustian KM, Morrow GR, et al,. 2005. Prevalence of complementary and alternative medicine use in cancer patients during treatment. Support Care Cancer 13: 806-811.
47. Yokosuka A, Mimaki Y., 2008. Steroidal glycosides from the underground parts of Trillium erectum and their cytotoxic activity. Phytochemistry 69: 2724-2730.